Lumiliximab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lumiliximab" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

195^th place

302^nd place

274^th place

309^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

102^nd place

76^th place

1semanticscholar.org

11^th place

8^th place

clinicaltrials.gov

Clinical trial number NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at ClinicalTrials.gov

doi.org

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–95. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. hdl:2318/1577053. PMID 25130401. S2CID 25789983.

handle.net

hdl.handle.net

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. hdl:2318/1577053. PMID 25130401. S2CID 25789983.

nih.gov

pubmed.ncbi.nlm.nih.gov

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–95. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. hdl:2318/1577053. PMID 25130401. S2CID 25789983.

ncbi.nlm.nih.gov

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–95. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.

semanticscholar.org

api.semanticscholar.org

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. hdl:2318/1577053. PMID 25130401. S2CID 25789983.

springer.com

adisinsight.springer.com

"Lumiliximab". Adis Insight. Springer Nature Switzerland AG.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (3). 2004.